Recruiting

A1c & TSH

Sponsor:

UCLA

Code:

NCT06993805

Conditions

Physician Workflow

Resource Utilization

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

OPA

Study Details

Brief summary:

Our Practice Advisory (OPA) are essential tools in clinical decision-making. The alerts are designed to guide providers towards evidence-based practices and improve patient outcomes. The focus of this initiative is on Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) testing, with the goal of addressing unnecessary repeat testing within a 30-day timeframe, which rarely yields significant new insights. Although randomization occurs at the patient level, the primary outcome of this study focuses on provider behavior and decision-making.

By focusing on this specific intervention, the study aims to optimize resource use, align test ordering with evidence-based guidelines, and support improved patient outcomes. The results of this evaluation will help refine OPAs and guide broader strategies for implementing clinical decision support tools across healthcare systems.

Conditions

Physician Workflow

Resource Utilization

Study ID

NCT06993805

Start date

May 6, 2025

Status verified date

May, 2025

Completion date

Feb, 2026

Anticipated

Primary completion date

Dec, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 years or older
  • Inpatient or observation stays within UCLA Health System hospitals
  • Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) ordered, AND this lab was ordered and resulted within the prior 30 days

Exclusion Criteria:

  • Have an A1c or TSH ordered and do not have a result for one of these labs in the prior 30 days

Study Design

Enrollment

384 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: OPA Intervention Group

Providers in this group will receive a Our Practice Advisory (OPA) through the electronic health record (EHR) system when ordering Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests. The OPA will prompt providers to reconsider the test if it was ordered within the previous 30 days, aligning with evidence-based guidelines to reduce unnecessary testing.

no intervention: Control Group

Providers in this group will not receive a Our Practice Advisory (OPA) through the Electronic Health Record (EHR) system when ordering Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests. This group represents the current standard of care, with no additional prompts or alerts implemented.

Interventions

OPA

The Our Practice Advisory (OPA) intervention is a behavioral nudge integrated into the electronic health record system. It is designed to prompt providers to reconsider ordering Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests if a similar test was performed within the previous 30 days. The OPA aligns with evidence-based guidelines to reduce unnecessary testing, improve resource utilization, and optimize patient care by enhancing clinical decision-making at the point of order entry.

Primary outcome measure

  • Change in Frequency of Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) Ordered within 30 days of Prior Results [ Time Frame: Study month 6 ]

Central Contacts and Locations

Central contacts

Katelyn Clinical Research Coordinator

310-267-5250katenguyen@mednet.ucla.edu

Locations

UCLA Health System

Recruiting

Los Angeles, California, United States, 90024

Contacts

Katelyn Clinical Research Coodinator

310-267-5250katenguyen@mednet.ucla.edu

More Information

Sponsor

University of California, Los Angeles

Last update posted

May 29, 2025

Last verified

May, 2025

Keywords

  • Clinical Decision Support
  • Laboratory Test Optimization
  • Resource Utilization
  • Our Practice Advisory (OPA)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of California, Los Angeles on 2025-05-29.